CEP-9722

DRUG3 trials

Sponsors

Cephalon, Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Solid TumorSolid TumorsSolid Tumors or Mantle Cell Lymphoma

Phase 1

Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid Tumors

CompletedNCT00920595

CephalonSolid Tumor

Start: 2009-06-30End: 2011-10-31Updated: 2012-08-16

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

TerminatedNCT01311713

Teva Branded Pharmaceutical Products R&D, Inc.Solid Tumors

Start: 2011-05-02End: 2013-10-16Updated: 2024-01-30

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

CompletedNCT01345357

CephalonSolid Tumors or Mantle Cell Lymphoma

Start: 2011-05-31End: 2013-01-31Updated: 2013-01-18